Related Experiment Video
Updated: Aug 6, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Definitive Cefmetazole Therapy for Pediatric ESBL-producing Enterobacterales Bacteremia
Yuto Otsubo1,2, Yo Murata1,2, Kazue Kinoshita3
1From the Division of Infectious Diseases, Immunology, Department of Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
None:
This retrospective study evaluated clinical outcomes of cefmetazole, a cephamycin, compared with carbapenems as definitive therapy for pediatric bacteremia caused by extended-spectrum β-lactamase-producing Enterobacterales. Among 43 patients, outcomes with cefmetazole (n = 17) were comparable to those with meropenem (n = 26), including 30-day mortality and recurrence. Cefmetazole may be a carbapenem-sparing option for pediatric extended-spectrum β-lactamase-producing Enterobacterales bacteremia.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Bacterial DNA Synthesis
